Hematologic effects of inactivating the Ras processing enzyme Rce1

Abigail L Aiyagari1, Brigit R Taylor, Vikas Aurora

  • 1Department of Pediatrics, Gladstone Institute of Cardiovascular Disease, University of California, San Francisco (UCSF), CA 94143, USA.

Blood
|November 16, 2002
PubMed

Insights

Pharmacologic inhibitors targeting Rce1, an enzyme crucial for Ras protein processing, show minimal impact on normal hematopoietic cells. Rce1 mutant cells effectively repopulated recipients, indicating Rce1 is not essential for hematopoiesis.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Ras proteins require posttranslational processing for membrane targeting.
  • Rce1 is an endoprotease that cleaves the CAAX motif, releasing the C-terminal amino acids.
  • Rce1 plays a role in Ras protein prenylation and localization.

Purpose of the Study:

  • To investigate the role of Rce1 in hematopoiesis.
  • To assess the impact of Rce1 deficiency on hematopoietic stem and progenitor cells.
  • To evaluate the potential of Rce1 as a therapeutic target for anticancer drug discovery.

Main Methods:

  • Adoptive transfer of Rce1(-/-) fetal liver cells into lethally irradiated recipients.
  • Competitive repopulation assays to assess long-term repopulating potential.
  • Analysis of hematopoietic cell populations and extracellular signal-related kinase (ERK) activation.

Main Results:

  • Rce1(-/-) fetal liver cells rescued recipients and exhibited normal long-term repopulating capacity.
  • Recipients of Rce1(-/-) cells showed modest increases in mature myeloid cells without adverse effects.
  • Bone marrow cells from Rce1(-/-) transplants activated ERK normally in response to GM-CSF.

Conclusions:

  • Rce1 is not essential for normal hematopoietic stem cell function and long-term repopulation.
  • Pharmacologic inhibition of Rce1 is unlikely to significantly affect normal hematopoietic cells.
  • These findings suggest Rce1 inhibitors may have a favorable safety profile for anticancer therapy.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...